Explore / Peer-reviewed article
Peer-reviewed article

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris RiD, Croal M, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RWiD, Marwood L, Nowakowska A, Páleníček T, Repantis D, Schoevers RAiD, Simmons H, Soares JC, Somers M, Tsai J, Wahba MiD, Williams E, Young AH, Young MB, Zisook S, Malievskaia E

Journal of affective disordersMar 23, 2026United Kingdom, United States, Spain, Canada, Ireland, Denmark, Czech Republic, Germany, Netherlands3 citationsDOI: 10.1016/j.jad.2026.121662

Abstract

<h4>Introduction</h4>The contribution of patient support to psilocybin's antidepressant effects remains uncertain.<h4>Methods</h4>Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression Rating Scale; MADRS) were explored using correlation and path analysis for individuals with treatment-resistant depression receiving 25 mg psilocybin with monitoring and support (N = 79).<h4>Results</h4>Change from Baseline to Week 3 MADRS scores showed weaker correlations with pre-dosing therapeutic alliance (-0.178) than with measures of the psychedelic experience: EBI (-0.637), Oceanic Boundlessness (-0.508), and Visual Restructuralization (-0.516). Path analysis showed no nominally significant direct effects of therapeutic alliance on Week 3 MADRS scores, but there were nominally significant effects of therapeutic alliance on psychedelic experience (Oceanic Boundlessness (β = 0.28), Visual Restructuralization (β = 0.27), and Auditory Alterations (β = 0.25)). Only one indirect effect of therapeutic alliance on clinical outcome reached nominal significance (via Visual Restructuralization; β = -0.15). Stronger effects were seen on clinical outcomes for psychedelic experience (EBI (β = -0.59), Oceanic Boundlessness (β = -0.53), Visual Restructuralization (β = -0.54), and Auditory Alterations (β = -0.24)).<h4>Conclusions</h4>The therapeutic alliance appeared to facilitate the psychedelic experience, and these experiences in turn had stronger nominally significant direct effects on clinical outcomes. The effects of the alliance itself on therapeutic efficacy were either limited or absent.<h4>Trial registration</h4>EudraCT number: 2017-003288-36; Clinicaltrials.gov identifier: NCT03775200.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

Psychological SupportTherapeutic AllianceTreatment-resistant DepressionPsychedelic Experience

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.